Drug intelligence / Profile preview

SHR-2010

Development stage: Discontinued
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

SHR-2010 is a monoclonal antibody drug candidate developed by Guangdong Hengrui Pharmaceutical for the treatment of IgA nephropathy. It acts as an inhibitor of MASP2 protein, a key enzyme in the lectin pathway of complement activation, which is implicated in the pathogenesis of IgA nephropathy. The drug is administered intravenously or subcutaneously and has reached Phase 2 clinical trials for primary IgA nephropathy (glomerulonephritis). As of now, it has not received regulatory approval in any country[1][2][3][4].

Other names: SHR 2010SHR2010SHR-2010

Targets

MASP2 (Mannan-binding lectin-associated serine protease 2)

Beyond the preview

Go deeper on SHR-2010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2010.

Explore the full profile